NEW YORK (GenomeWeb News) – The National Human Genome Research Institute said this week that it has chosen Daniel Kastner to be its new scientific director. Kastner, who will join NHGRI in October, currently is clinical director and director of translational research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
In his new role Kastner will run NHGRI's Division of Intramural Research, which has an annual budget of around $105 million, about 50 faculty-level investigators, and roughly 500 other staff members.
Former Genome Canada President and CEO Martin Godbout has been appointed chairman of MethylGene's board of directors. Godbout, who held the top post at Genome Canada between 2000 and 2009, has served as a member of MethylGene's board since 2002. He also has been senior VP of BioCapital and president and GM of Société Innovatech Québec.
Primera Dx has appointed Matthew McManus to take over the job of president and CEO and to serve on the firm's board of directors. McManus came to PrimeraDx from his position as head of Cleveland Clinical Laboratories and COO of the Pathology and Laboratory Medicine Institute. He also previously served as a scientist for the Novartis Biomedical Research Drug Discovery Incubator, a consultant at McKinsey & Company, and he was involved in sales and marketing at Procter & Gamble.
The Van Andel Institute has appointed four new staff members and a new appointee to its graduate school board. VAI's new staff includes Scott Jewell as director of the Program for Bioscpecimen Science; Jianfeng Xu as director of the Program for Genetic Epidemiology; Matthew Steensma as scientific investigator and head of the Laboratory of Musculoskeletal Oncology; and Dan Rohrer as operations director for the Program for Biospecimen Science. The institute also has appointed Thomas Haas to serve on the VAI Graduate School Board of Directors.
Norrie Russell has been named president of Ocimum Biosolutions subsidiary Gene Logic. Russell has held leadership roles at AstraZeneca, Invitrogen, Aviva Biosciences, and Lynx Therapeutics.
"We are extremely excited about getting Dr. Russell on board as we progress our Research as a Service (RaaS) offerings," Ocimum Biosolutions CEO Anu Acharya said in a statement. "Norrie brings leadership that is a unique blend of experience, education, and enthusiasm to take Ocimum Biosolutions to the next level."
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.